# A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02731846** · PHASE3 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg
- **DRUG:** Fluticasone furoate 100 mcg + Vilanterol 25 mcg
- **DRUG:** Umeclidinium 62.5 mcg
- **DEVICE:** Placebo ELLIPTA inhaler
- **DRUG:** Albuterol/Salbutamol

## Key facts

- **NCT ID:** NCT02731846
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** It has been determined on June 10th that the 205165 study will not progress. This decision has been made prior to study start, no patients were screened.
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02731846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02731846, "A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02731846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*